Introduction
The risk for thrombus formation associated with prosthetic heart valves is up to seven times greater within the first month after valve replacement than it is during the following months and years, irrespective of the intra-cardiac position of the device [1] . Underlying pathophysiological factors are activation of the extrinsic and intrinsic coagulation systems by synthetic surfaces of the extracorporeal circulation, or by contact of blood with foreign surfaces (sutures, sewing ring, occluder), or at sites of collagen or denuded tissue [2] [3] [4] . Shear stress arising in the vicinity of valvular implants adds activated platelets as a source of thrombus [5] . Frequently, arrhythmias and perioperative haemodynamic disturbances further increase the thromboembolic risk. Coagulopathy results from activation of coagulation and decrease in inhibitors, and a reactive increase in fibrinogen and platelet count (following an initial decrease caused by platelet consumption and complement activation during extra-corporeal circulation) [6] .
The importance of chronic anticoagulation after heart valve replacement with mechanical devices is generally accepted; recommendations for anticoagulation [7] [8] [9] [10] [11] have been formulated by several working groups (Table 1) .
Those guidelines were recently redefined with respect to the level of anticoagulation and laboratory monitoring required, but provide only scarce information regarding early management of anticoagulation after heart valve replacement. This is due to a lack of randomized studies that address this important issue.
The following aspects of anticoagulation management during the immediate postoperative period are of major interest: when anticoagulation should be started; what dosage of oral anticoagulant is appropriate; how anticoagulation should be monitored; and how anticoagulation should be managed until stable oral anticoagulation is achieved.
Introduction of anticoagulation during the immediate postoperative period
Early anticoagulation with unfractionated heparin (UFH) is recommended [7] [8] [9] [10] [11] , but great variation exists among protocols in various surgical units and countries. A substantial number of surgeons favour delay of anticoagulation because of the risk of bleeding. The incidence of pericardial tamponade and surgical reintervention is up to eight times greater in patients treated with high-dose heparin than in those treated with low-dose heparin for prevention of venous thrombosis [12, 13] . following the start of anticoagulation. Occurrence of this threatening complication is frequently associated with episodes of hyper-anticoagulation [13] . Therefore, protocols should aim to avoid over-aggressive anticoagulation.
Dosage regimen of coumarins
In the past, oral anticoagulation was initiated with high loading doses of warfarin in order to shorten the time period until the desired level of anticoagulation is achieved. This strategy has obvious disadvantages; an International Normalized Ratio (INR) greater than 2 is achieved significantly earlier with a loading dose of 10 mg or greater than with a dose of 5 mg, but higher INR values do not indicate sufficient antithrombotic effects [14, 15] . INR increase reflects early reduction in factor VII (half-life 5 h), whereas factor II (half-life 72 h) is still in a non-therapeutic range. Also, further depression of thrombin formation cannot be achieved with higher loading doses of oral anticoagulant [16] . Combined with a rapid decrease in levels of vitamin K dependant inhibitor protein C, a temporary hypercoagulable state can result. Furthermore, the higher incidence of cutis necrosis with higher warfarin loading doses in patients with protein C deficiency supports the recommendation to employ low-dose initiation protocols. In addition, high-dose protocols may result in hypocoagulation and increased risk for bleeding, because the individual response to coumarins is generally greater following heart valve surgery [17] . A decrease in albumin, reduced concentrations of coagulation factors, the state of the protein C system at the end of extracorporeal circulation, and advanced age account for this finding [17] [18] [19] . Current guidelines recommend that dosage regimens be adapted to the patient's condition, age, and heart and liver function. For the majority of patients after heart valve replacement, doses of less than 10 mg warfarin appear preferable [8, 20] . That finding is from studies that addressed the use of warfarin, but no similar studies that address use of phenprocoumon exist. Platelet activation caused by shear stress may be anticipated as a source of thrombus formation on mechanical heart valve surfaces [5] . This has led to the recommendation to administer a platelet inhibitor to patients with significant risk factors or previous thromboembolic events [8] . Studies that added aspirin to warfarin showed benefits with regard to thromboembolic complications, but also reported increased risk of bleeding [21] . Therefore, at present, platelet inhibitors cannot be recommended during the early postoperative period.
Concomitant heparin therapy
In the current guidelines the use of UFH is recommended early after the procedure [7] [8] [9] [10] [11] . As additional experience is gained with other indications, the use of low-molecularweight heparin (LMWH) must be considered. Thus far no controlled studies have been conducted regarding LMWH and the initiation of oral anticoagulation. The following characteristics support the use of LMWH during the induction of oral anticoagulation [22] : longer half-life; more predictable dose responses; reduction in the need for laboratory monitoring; and greater bioavailability following subcutaneous administration, allowing a more convenient mode of administration without the need for an intravenous line.
LMWH has been used in selected cases after the immediate postoperative period, when anticoagulation stabilizes, because of pregnancy [23] or contraindications to coumarins [24] , with favourable results. Cases of treatment
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Eur Heart J Supplements, Vol. 3 (Suppl Q) December 2001 [9] British Society for Haematology [8] American Heart Association [11] Type of heparin UFH UFH UFH failure can clearly be attributed to inadequate doses [25] . Montalescot et al. [26] conducted a comparative, nonrandomized study in patients following after heart valve replacement. Those investigators demonstrated that therapeutic anti-Xa levels can be achieved within 2 days after starting LMWH administration in more than 90% of patients treated with weight-adjusted doses, without an increase in bleeding or incidence of thromboembolic complications. LMWH may carry a substantial economic advantage in the present era of diminishing resources. Intravenous heparin therapy often prolongs hospital stay, whereas the use of LMWH could allow ambulatory care and thereby might significantly reduce hospital costs. Laboratory controls are not needed (as demonstrated with treatment of deep vein thrombosis [27] ), except for conditions that lead to the accumulation of LMWH, thus making treatment easier. More intensive use of LMWH requires further evaluation in prospective randomized studies, however.
Monitoring
Currently, INR has replaced partial thromboplastin time as a laboratory parameter for monitoring anticoagulation with oral anticoagulants [7] [8] [9] [10] [11] . During the initial phase of oral anticoagulation, however, INR in the therapeutic range does not necessarily indicate sufficient anticoagulation because of the different half-lives of the coagulation factors [28] . Continuation of heparin therapy for 2 consecutive days once INR is in the therapeutic range is advisable to prevent potential thromboembolic events [8, 28] . If intravenous UFH is used, then partial thromboplastin time should be measured [7] .
LMWH requires laboratory testing (anti-Xa activity) only in those patients with an increased risk of accumulation (renal insufficiency, pregnancy, very high/low body weight) or abnormal bleeding characterstics [29] .
Conclusion
In order to prevent early thromboembolic complications after heart valve replacement, anticoagulation should be started within 24 h after the procedure using intravenous UFH or subcutaneous LMWH. Sufficient anticoagulation can be achieved with subcutaneous LMWH. Laboratory testing is only necessary in those cases in which there is a risk of LMWH accumulation. With UFH, frequent monitoring of partial thromboplastin time is mandatory. Further studies are necessary to evaluate whether LMWH is associated with a higher incidence of bleeding complications. Oral anticoagulation should be initiated preferably with low doses of coumarins in order to avoid hypercoagulable conditions. INR levels measured early postoperatively do not represent the actual coagulation status because of the high sensitivity of the thromboplastin reagents to factor VII. Therefore, heparin treatment should be continued until INR is within the therapeutic range for more than 2 days, or molecular markers should be recorded to improve management. There is a need for further data regarding the management of early anticoagulation following heart valve replacement.
